New hope for nighttime cluster headaches: Low-Sodium drug enters trial
NCT ID NCT06950281
First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This phase 2 trial tests whether low sodium oxybate (Xywav) can reduce nighttime cluster headache attacks in people with chronic cluster headache. About 52 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug lowers the number of headaches that occur during sleep.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC CLUSTER HEADACHE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low sodium oxybate (Xywav)
What this could lead to
If it works, this could provide a new treatment option to reduce painful nighttime cluster headache attacks.
What could go wrong
This is an early phase 2 trial with only 52 participants, so results may not apply to everyone. The drug may cause side effects or not work better than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.